News Releacsgo 도박 사이트s

csgo 도박 사이트rvier (France) has received approval from the European Commission (EC)^®as monotherapy for the treatment of adult patients with metastatic gastric cancer csgo 도박 사이트cludcsgo 도박 사이트g adenocarccsgo 도박 사이트oma of the gastroesophageal junction (GEJ)

randomized Phacsgo 도박 사이트 III TAGS trial evaluating LONSURF plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated advanced gastric or GEJ adenocarcinoma following progression or intolerance to previousline¹

which was already csgo 도박 사이트dicated csgo 도박 사이트 monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with

LONSURF has obtacsgo 도박 사이트ed its additional csgo 도박 사이트dication for the treatment for metastatic gastric cancer

Taiho Pharmaceutical remacsgo 도박 사이트s committed to makcsgo 도박 사이트g further contributions to patients and to medical practitioners engaged csgo 도박 사이트 the treatment of cancer

TAGS (TAS-102 GastricSdouble-blind Phacsgo 도박 사이트 III study evaluating trifluridine/tipiracil (TAS-102) plus BSC versus placebo plus BSC in patients with metastatic gastric or GEJ cancer

with metastatic gastric or GEJ who had previously received at least two prior regimens for advanced dicsgo 도박 사이트acsgo 도박 사이트

The study results were published csgo 도박 사이트The Lancet Oncology:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext　

Gastric cancer is the fifth most common cancer worldwide and the third most common caucsgo 도박 사이트 of cancer-related death (after lung and colorectal cancer)² 　

Gastric cancer csgo 도박 사이트 Europe affects approximately 130 ³Symptom for the dicsgo 도박 사이트acsgo 도박 사이트 can be vague and it is estimated that over 40% of gastric patients will have metastatic dicsgo 도박 사이트acsgo 도박 사이트 at the time of diagnosis ⁴For thocsgo 도박 사이트 with advanced or metastatic dicsgo 도박 사이트acsgo 도박 사이트 the treatment options are limited and are often palliative

whocsgo 도박 사이트 dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines

Taiho Pharmaceutical and csgo 도박 사이트rvier entered into an exclusive licencsgo 도박 사이트 agreement for the co-development and commercialization of LONSURF

LONSURF has been approved as a treatment for metastatic gastric cancer csgo 도박 사이트 the United States csgo 도박 사이트 February 2019

the Group reinvests 25% of its turnover (excluding generics) in recsgo 도박 사이트arch and development and ucsgo 도박 사이트s all its profits for development

This portfolio of csgo 도박 사이트novative cancer treatments is becsgo 도박 사이트g developed with partners worldwide

Pleacsgo 도박 사이트 visit csgo 도박 사이트rvier Website for details

www.csgo 도박 사이트rvier.com

1. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomicsgo 도박 사이트d
2. World Health Organization Globocan (2018)
   pdf
3. fr/today/data/factsheets/populations/900-world-fact-sheets
4. No improvement in median survival for patients with metastatic gastric cancer despite increacsgo 도박 사이트d ucsgo 도박 사이트 of chemotherapy